← All trials
NCT07217496
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- May 30, 2027
- Completion date
- May 30, 2027
- First posted
- Oct 16, 2025
- Last posted
- Oct 16, 2025
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOfficial
- ImmunityBio, Inc.Collaborator
- University of California, San FranciscoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.